Harmony TPV Post-Approval Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05077774 |
Recruitment Status :
Recruiting
First Posted : October 14, 2021
Last Update Posted : March 15, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Congenital Heart Disease Tetrology of Fallot RVOT Anomaly Pulmonary Regurgitation | Device: Harmony TPV System | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 150 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Harmony TPV Post-Approval Study (Harmony PAS2) |
Actual Study Start Date : | October 25, 2021 |
Estimated Primary Completion Date : | September 2023 |
Estimated Study Completion Date : | March 2033 |

Arm | Intervention/treatment |
---|---|
Harmony TPV System
Intervention Device: Harmony Transcatheter Pulmonary Valves and Delivery System
|
Device: Harmony TPV System
Harmony Transcatheter Pulmonary Valve (sizes 22 mm and 25 mm) and Harmony Delivery Catheter System (DCS)
Other Name: Model Numbers: HARMONY-22, HARMONY-25, and HARMONY-DCS |
- Proportion of subjects without valve reintervention and with acceptable hemodynamic function composite at 6 months as defined by: [ Time Frame: 6 months ]
- Mean RVOT gradient as measured by continuous-wave Doppler echocardiography ≤40 mmHg AND
- Pulmonary regurgitant fraction as measured by CMR <20%
- Percentage of subjects free from all-cause mortality at 6-months [ Time Frame: 6 months ]Described by Kaplan-Meier statistics at 6-months.
- Percentage of subjects free from reoperation at 6-months [ Time Frame: 6 months ]Described by Kaplan-Meier statistics at 6-months.
- Percentage of subjects free from catheter reintervention at 6-months [ Time Frame: 6 months ]Described by Kaplan-Meier statistics at 6-months.
- Percentage of subjects free from TPV dysfunction at 6-months [ Time Frame: 6 months ]Described by Kaplan-Meier statistics at 6-months.
- Number and percentage of subjects with procedure success at 30-days [ Time Frame: 30-days ]
- Number and percentage of subjects with serious device-related adverse events at 6 months [ Time Frame: 6 months ]Also described with Kaplan-Meier method for AEs of clinical interest.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient eligible to receive the Harmony TPV, meeting the indications for use criteria per current geography-specific device labeling at time of study enrollment
- Patient (or patient's legally authorized representative) is willing to consent to participate in the study
Exclusion Criteria:
- Anatomy unable to accommodate a 25 Fr delivery catheter system
- Obstruction of the central veins
- Clinical or biological signs of infection including active endocarditis
- Planned concomitant branch pulmonary artery stenting at time of implant
- Positive pregnancy test at baseline (prior to CT angiography and again prior to implant procedure) in female subjects of childbearing potential
- Patients with right ventricular outflow tract obstruction (RVOTO) lesions surgically treated with an RV-PA conduit implant
- A major or progressive non-cardiac disease (e.g. liver failure, renal failure, cancer) that results in a life expectancy of less than one year
- Planned implantation of the Harmony TPV in the left heart
- Known allergy to aspirin, heparin, or nickel
- Echocardiographic evidence of intracardiac mass, thrombus, or vegetation
- Pre-existing prosthetic heart valve or prosthetic ring in any position

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05077774
Contact: Michelle Vanney | 763-514-4000 | RS.HarmonyPAS2@medtronic.com | |
Contact: Harmony Clinical Study Central Email | RS.HarmonyPAS2@medtronic.com |

Principal Investigator: | David Balzer, MD | St. Louis Children's Hospital |
Responsible Party: | Medtronic Cardiovascular |
ClinicalTrials.gov Identifier: | NCT05077774 |
Other Study ID Numbers: |
MDT20057CON003 |
First Posted: | October 14, 2021 Key Record Dates |
Last Update Posted: | March 15, 2023 |
Last Verified: | March 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | Yes |
Heart Diseases Heart Defects, Congenital Pulmonary Valve Insufficiency Tetralogy of Fallot |
Cardiovascular Diseases Cardiovascular Abnormalities Congenital Abnormalities Heart Valve Diseases |